Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
Pharmaceuticals (Basel, Switzerland)
|
October 23, 2021
Combination Therapies with PRRT
Anna Yordanova, Hojjat Ahmadzadehfar
Journal of Clinical Medicine
|
November 19, 2020
Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
Anna Yordanova, Hans-Jürgen Biersack, Hojjat Ahmadzadehfar
Current Pharmaceutical Design
|
February 19, 2020
Bench-to-Bedside Theranostics in Nuclear Medicine
Narges Jokar, Majid Assadi, Anna Yordanova, et al.
Clinical Nuclear Medicine
|
November 8, 2016
Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis
Anna Yordanova, Karin Mayer, Markus Essler, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India
|
March 1, 2017
[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
Anna Yordanova, Carl Schlenkhoff, Holger Palmedo, et al.
Clinical Nuclear Medicine
|
July 13, 2016
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer
Hojjat Ahmadzadehfar, Carl Diedrich Schlenkhoff, Sebastian Rogenhofer, et al.
PET Clinics
|
May 31, 2021
An Impressive Approach in Nuclear Medicine: Theranostics
Nasim Vahidfar, Elisabeth Eppard, Saeed Farzanehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 15, 2017
Delayed response after repeated <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar, Martin Bögeman, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 9, 2016
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
Kambiz Rahbar, Matthias Schmidt, Alexander Heinzel, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 25, 2017
The impact of repeated cycles of radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova, Anja Becker, Elisabeth Eppard, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
Pharmaceuticals (Basel, Switzerland)
|
October 23, 2021
Combination Therapies with PRRT
Anna Yordanova, Hojjat Ahmadzadehfar
Journal of Clinical Medicine
|
November 19, 2020
Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
Anna Yordanova, Hans-Jürgen Biersack, Hojjat Ahmadzadehfar
Current Pharmaceutical Design
|
February 19, 2020
Bench-to-Bedside Theranostics in Nuclear Medicine
Narges Jokar, Majid Assadi, Anna Yordanova, et al.
Clinical Nuclear Medicine
|
November 8, 2016
Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis
Anna Yordanova, Karin Mayer, Markus Essler, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India
|
March 1, 2017
[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
Anna Yordanova, Carl Schlenkhoff, Holger Palmedo, et al.
Clinical Nuclear Medicine
|
July 13, 2016
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer
Hojjat Ahmadzadehfar, Carl Diedrich Schlenkhoff, Sebastian Rogenhofer, et al.
PET Clinics
|
May 31, 2021
An Impressive Approach in Nuclear Medicine: Theranostics
Nasim Vahidfar, Elisabeth Eppard, Saeed Farzanehfar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 15, 2017
Delayed response after repeated <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar, Martin Bögeman, Anna Yordanova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 9, 2016
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
Kambiz Rahbar, Matthias Schmidt, Alexander Heinzel, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 25, 2017
The impact of repeated cycles of radioligand therapy using [<sup>177</sup>Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova, Anja Becker, Elisabeth Eppard, et al.
Page
of 3